LoginRegister
    Astellas Pharma acquires Xyphos for USD 665 millionAstellas Pharma acquires Xyphos for USD 665 million
    Correvio Pharma heart drug Brinavess fails to get USFDA nodCorrevio Pharma heart drug Brinavess fails to get USFDA nod
    Lannett gets USFDA nod for Butalbital, Acetaminophen and Caffeine CapsulesLannett gets USFDA nod for Butalbital, Acetaminophen and Caffeine Capsules
    Rational Use Of Antibiotics For Limiting Antimicrobial Resistance: CDSCO lists down steps for Pharma cos, chemists and drug controllersRational Use Of Antibiotics For Limiting Antimicrobial Resistance: CDSCO lists down steps for Pharma...
    Dishman Carbogen shares rise by 9 pc after I-T department conducts search at officesDishman Carbogen shares rise by 9 pc after I-T department conducts search at offices
    Allergan signs $750 million settlement with purchasers of AlzheimerAllergan signs $750 million settlement with purchasers of Alzheimer's drug Namenda
    Piramal Enterprises to raise Rs 2,750 crore by issuing bonds on private placement basis.Piramal Enterprises to raise Rs 2,750 crore by issuing bonds on private placement basis.
    Eurolife Healthcare acquires intravenous infusion business of Teva, HungaryEurolife Healthcare acquires intravenous infusion business of Teva, Hungary
    Punjab: 50-year-old pharmacist harassed, blackmailed, extorted of Rs 6 lakh; constable heldPunjab: 50-year-old pharmacist harassed, blackmailed, extorted of Rs 6 lakh; constable held
    Alembic Pharma glaucoma drug Travoprost Ophthalmic Solution gets USFDA approvalAlembic Pharma glaucoma drug Travoprost Ophthalmic Solution gets USFDA approval
    Granules India gets USFDA nod for allergy treatment drug LoratadineGranules India gets USFDA nod for allergy treatment drug Loratadine
    Roche to pay USD 1.15 billion to Sarepta for gene therapy licensing dealRoche to pay USD 1.15 billion to Sarepta for gene therapy licensing deal
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X